Search research articles
Contact Us
Filters
Showing results (341-350 of 371) with videos related to
Page
of 38
Sort By:
Autophagy
|
July 4, 2014
YY1-MIR372-SQSTM1 regulatory axis in autophagy
Lifeng Feng, Yanning Ma, Jie Sun, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 20, 2026
Interpretable Artificial Intelligence in Assisting Treatment Response Prediction for Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy: A Prospective, Multicenter, Human-Model Interaction Study
Xiaolin Pang, Xiaobo Chen, Guangdong Zeng, et al.
Oncoimmunology
|
June 15, 2018
CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
Yao Wang, Meixia Chen, Zhiqiang Wu, et al.
Nature Communications
|
January 19, 2021
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
Yao Wang, Chuan Tong, Hanren Dai, et al.
Oncotarget
|
September 13, 2015
p53 controls colorectal cancer cell invasion by inhibiting the NF-κB-mediated activation of Fascin
Xinbing Sui, Jing Zhu, Haimei Tang, et al.
Oncotarget
|
September 30, 2016
The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
Tengfei Zhang, Jing Xie, Seiji Arai, et al.
Nature Communications
|
April 15, 2026
Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial
Chunmeng Wang, Yelei Guo, Fuxin Han, et al.
Journal of Immunology Research
|
June 26, 2014
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report
Hui Fan, Xuechun Lu, Xiaohui Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2019
Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
Jing Nie, Chunmeng Wang, Yang Liu, et al.
Cell Research
|
August 26, 2020
Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy
Mengze Lv, Meixia Chen, Rui Zhang, et al.
Page
of 38
Search research articles
Search
Showing results (341-350 of 371) with videos related to
Sort By:
Page
of 38
Autophagy
|
July 4, 2014
YY1-MIR372-SQSTM1 regulatory axis in autophagy
Lifeng Feng, Yanning Ma, Jie Sun, et al.
International Journal of Radiation Oncology, Biology, Physics
|
January 20, 2026
Interpretable Artificial Intelligence in Assisting Treatment Response Prediction for Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy: A Prospective, Multicenter, Human-Model Interaction Study
Xiaolin Pang, Xiaobo Chen, Guangdong Zeng, et al.
Oncoimmunology
|
June 15, 2018
CD133-directed CAR T cells for advanced metastasis malignancies: A phase I trial
Yao Wang, Meixia Chen, Zhiqiang Wu, et al.
Nature Communications
|
January 19, 2021
Low-dose decitabine priming endows CAR T cells with enhanced and persistent antitumour potential via epigenetic reprogramming
Yao Wang, Chuan Tong, Hanren Dai, et al.
Oncotarget
|
September 13, 2015
p53 controls colorectal cancer cell invasion by inhibiting the NF-κB-mediated activation of Fascin
Xinbing Sui, Jing Zhu, Haimei Tang, et al.
Oncotarget
|
September 30, 2016
The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
Tengfei Zhang, Jing Xie, Seiji Arai, et al.
Nature Communications
|
April 15, 2026
Demethylation-primed tandem CD19/CD20 CAR T cells in relapsed/refractory B-cell lymphoma: a phase I/II trial
Chunmeng Wang, Yelei Guo, Fuxin Han, et al.
Journal of Immunology Research
|
June 26, 2014
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report
Hui Fan, Xuechun Lu, Xiaohui Wang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 1, 2019
Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma
Jing Nie, Chunmeng Wang, Yang Liu, et al.
Cell Research
|
August 26, 2020
Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy
Mengze Lv, Meixia Chen, Rui Zhang, et al.
Page
of 38